{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T20:18:30Z","timestamp":1777493910149,"version":"3.51.4"},"reference-count":41,"publisher":"SAGE Publications","issue":"7","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Child and Adolescent Psychopharmacology"],"published-print":{"date-parts":[[2015,9]]},"abstract":"<jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>The efficacy of both methylphenidate and atomoxetine has been established in placebo-controlled trials. The present study aimed to directly compare the efficacy of methylphenidate and atomoxetine in improving symptoms among children with attention-deficit\/hyperactivity disorder (ADHD).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>\n                      The study sample included 160 drug-na\u00efve children and adolescents 7\u201316 years of age, with DSM-IV-defined ADHD, randomly assigned to osmotic-release oral system methylphenidate (OROS-methylphenidate) (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      =80) and atomoxetine (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      =80) in a 24 week, open-label, head-to-head clinical trial. The primary efficacy measure was the score of the ADHD Rating Scale-IV Parents Version: Investigator Administered and Scored (ADHD-RS-IV). The secondary efficacy measures included the Clinical Global Impressions\u2013ADHD\u2013Severity (CGI-ADHD-S) and Chinese Swanson, Nolan, and Pelham IV scale (SNAP-IV), based on the ratings of investigators, parents, teachers, and subjects.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      At week 24, mean changes in ADHD-RS-IV Inattention scores were 13.58 points (Cohen's\n                      <jats:italic toggle=\"yes\">d<\/jats:italic>\n                      , \u22123.08) for OROS-methylphenidate and 12.65 points (Cohen's\n                      <jats:italic toggle=\"yes\">d<\/jats:italic>\n                      , \u22123.05) for atomoxetine; and mean changes in ADHD-RS-IV Hyperactivity-Impulsivity scores were 10.16 points (Cohen's\n                      <jats:italic toggle=\"yes\">d<\/jats:italic>\n                      , \u22121.75) for OROS-methylphenidate and 10.68 points (Cohen's\n                      <jats:italic toggle=\"yes\">d<\/jats:italic>\n                      , \u22121.87) for atomoxetine. In terms of parent-, teacher-, and self-ratings on behavioral symptoms, both of the two treatment groups significantly decreased on the SNAP-IV scores at the end-point, with effect sizes ranging from 0.9 to 0.96 on the Inattention subscale and from 0.61 to 0.8 on the Hyperactivity\/Impulsivity subscale for OROS-methylphenidate; and from 0.51 to 0.88 on the Inattention subscale and from 0.29 to 0.57 on the Hyperactivity\/Impulsivity subscale for atomoxetine. No statistically significant differences between treatment groups were observed on the outcome measures. Vomiting, somnolence, and dizziness were reported more often for atomoxetine than for OROS-methylphenidate, whereas insomnia was reported more often for OROS-methylphenidate than for atomoxetine.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>After 24 weeks of treatment, OROS-methylphenidate and atomoxetine had comparable efficacy in reducing core ADHD symptoms in drug-na\u00efve children and adolescents with ADHD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1089\/cap.2015.0035","type":"journal-article","created":{"date-parts":[[2015,7,29]],"date-time":"2015-07-29T15:33:47Z","timestamp":1438184027000},"page":"566-573","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":31,"title":["An Open-Label, Randomized Trial of Methylphenidate and Atomoxetine Treatment in Children with Attention-Deficit\/Hyperactivity Disorder"],"prefix":"10.1177","volume":"25","author":[{"given":"Chi-Yung","family":"Shang","sequence":"first","affiliation":[{"name":"National Taiwan University Hospital","place":["Taiwan"]},{"name":"National Taiwan University","place":["Taiwan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi-Lei","family":"Pan","sequence":"additional","affiliation":[{"name":"National Taiwan University Hospital","place":["Taiwan"]},{"name":"Bali Psychiatric Center","place":["Taiwan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hsiang-Yuan","family":"Lin","sequence":"additional","affiliation":[{"name":"National Taiwan University Hospital","place":["Taiwan"]},{"name":"National Taiwan University","place":["Taiwan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lin-Wan","family":"Huang","sequence":"additional","affiliation":[{"name":"National Taiwan University Hospital","place":["Taiwan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan Shur-Fen","family":"Gau","sequence":"additional","affiliation":[{"name":"National Taiwan University Hospital","place":["Taiwan"]},{"name":"National Taiwan University","place":["Taiwan"]},{"name":"National Taiwan University","place":["Taiwan"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2015,9,1]]},"reference":[{"key":"e_1_3_3_2_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000188869.58300.a7"},{"key":"e_1_3_3_3_1","unstructured":"American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders 4th ed. Washington DC: American Psychiatric Association; 1994."},{"key":"e_1_3_3_4_1","doi-asserted-by":"publisher","DOI":"10.1177\/0269881113478475"},{"key":"e_1_3_3_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0893-133X(02)00346-9"},{"key":"e_1_3_3_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(03)90092-0"},{"key":"e_1_3_3_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1819.2009.01937.x"},{"key":"e_1_3_3_8_1","doi-asserted-by":"publisher","DOI":"10.1136\/archdischild-2013-304170"},{"key":"e_1_3_3_9_1","doi-asserted-by":"publisher","DOI":"10.1177\/070674370200601S04"},{"key":"e_1_3_3_10_1","doi-asserted-by":"publisher","DOI":"10.1186\/1753-2000-5-14"},{"key":"e_1_3_3_11_1","doi-asserted-by":"crossref","unstructured":"DuPaul GJ Power TJ Anastopoulos AD Reid R: ADHD Rating Scale-IV: Checklists Norms and Clinical Interpretations. New York: Guilford; 1998.","DOI":"10.1037\/t00680-000"},{"key":"e_1_3_3_12_1","first-page":"4","article-title":"Comparing the efficacy of medications for ADHD using meta-analysis","volume":"8","author":"Faraone SV","year":"2006","unstructured":"Faraone SV, , Biederman J, , Spencer TJ, , Aleardi M.: Comparing the efficacy of medications for ADHD using meta-analysis. MedGenMed, 8:4, 2006.","journal-title":"MedGenMed"},{"key":"e_1_3_3_13_1","first-page":"104","article-title":"The worldwide prevalence of ADHD: Is it an American condition?","volume":"2","author":"Faraone SV","year":"2003","unstructured":"Faraone SV, , Sergeant J, , Gillberg C, , Biederman J: The worldwide prevalence of ADHD: Is it an American condition?. World Psychiatry, 2:104\u201313, 2003.","journal-title":"World Psychiatry"},{"key":"e_1_3_3_14_1","doi-asserted-by":"publisher","DOI":"10.1177\/108705470100500204"},{"key":"e_1_3_3_15_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.162.7.1344"},{"key":"e_1_3_3_16_1","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2006.0091"},{"key":"e_1_3_3_17_1","doi-asserted-by":"publisher","DOI":"10.1093\/jpepsy\/jsn133"},{"key":"e_1_3_3_18_1","doi-asserted-by":"publisher","DOI":"10.1017\/S1461145709990836"},{"key":"e_1_3_3_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/mpr.237"},{"key":"e_1_3_3_20_1","doi-asserted-by":"publisher","DOI":"10.1097\/chi.0b013e3180ca8385"},{"key":"e_1_3_3_21_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.279.14.1100"},{"key":"e_1_3_3_22_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-244X-11-176"},{"key":"e_1_3_3_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF02849870"},{"key":"e_1_3_3_24_1","doi-asserted-by":"publisher","DOI":"10.1177\/1087054706289926"},{"key":"e_1_3_3_25_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004583-200207000-00008"},{"key":"e_1_3_3_26_1","doi-asserted-by":"publisher","DOI":"10.1097\/DBP.0b013e31824afea1"},{"key":"e_1_3_3_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00787-009-0042-7"},{"key":"e_1_3_3_28_1","doi-asserted-by":"publisher","DOI":"10.1177\/070674379904401008"},{"key":"e_1_3_3_29_1","doi-asserted-by":"publisher","DOI":"10.1185\/03007990903316152"},{"key":"e_1_3_3_30_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2007.05091676"},{"key":"e_1_3_3_31_1","doi-asserted-by":"publisher","DOI":"10.2165\/00148581-200810010-00005"},{"key":"e_1_3_3_32_1","doi-asserted-by":"publisher","DOI":"10.1093\/sleep\/29.12.1573"},{"key":"e_1_3_3_33_1","doi-asserted-by":"publisher","DOI":"10.2165\/00128072-200305060-00005"},{"key":"e_1_3_3_34_1","doi-asserted-by":"publisher","DOI":"10.1177\/030802260206500302"},{"key":"e_1_3_3_35_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00787-008-0725-5"},{"key":"e_1_3_3_36_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004583-200102000-00011"},{"key":"e_1_3_3_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.chc.2007.11.010"},{"key":"e_1_3_3_38_1","doi-asserted-by":"publisher","DOI":"10.1080\/00048670601057767"},{"key":"e_1_3_3_39_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpedi.160.1.82"},{"key":"e_1_3_3_40_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.108.4.883"},{"key":"e_1_3_3_41_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004703-200402000-00007"},{"key":"e_1_3_3_42_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10578-010-0212-3"}],"container-title":["Journal of Child and Adolescent Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/cap.2015.0035","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/cap.2015.0035","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/cap.2015.0035","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T14:56:35Z","timestamp":1777388195000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/cap.2015.0035"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9]]},"references-count":41,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2015,9]]}},"alternative-id":["10.1089\/cap.2015.0035"],"URL":"https:\/\/doi.org\/10.1089\/cap.2015.0035","relation":{},"ISSN":["1044-5463","1557-8992"],"issn-type":[{"value":"1044-5463","type":"print"},{"value":"1557-8992","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,9]]}}}